ArticleCell proliferation2021
Aptamer-conjugated mesoporous polydopamine for docetaxel targeted delivery and synergistic photothermal therapy of prostate cancer.
Article in Cell proliferation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 44 citations in OpenAlex.
- Fabrication of cercosporin-loaded polydopamine- cloaked mesoporous silica nanoparticles enhanced photothermal-photodynamic and anticancer activity in pancreatic cancer.Journal of materials science. Materials in medicine · 2026Article
- Fabrication of docetaxel-loaded PEG-modified calcium carbonate-loaded zeolite imidazole nanoframeworks for synergic gastric cancer photothermal therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Nanomaterials in gene therapy and genome editing: challenges and emerging directions.Journal of nanobiotechnology · 2025Review
- An aptamer-conjugated mesoporous polydopamine formulation for synergistic targeted and photothermal therapy of hepatocellular carcinoma.International journal of pharmaceutics: X · 2025Article
- Targeting AURKA with multifunctional nanoparticles in CRPC therapy.Journal of nanobiotechnology · 2024Article
- Aptamer-functionalized triptolide with release controllability as a promising targeted therapy against triple-negative breast cancer.Journal of experimental & clinical cancer research : CR · 2024Article
- Boosting antitumor efficacy using docetaxel-loaded nanoplatforms: from cancer therapy to regenerative medicine approaches.Journal of translational medicine · 2024Review
- Aptamer-Based Smart Targeting and Spatial Trigger-Response Drug-Delivery Systems for Anticancer Therapy.Biomedicines · 2024Review
- Mesoporous Polydopamine Nanotherapeutics for MRI-Guided Cancer Photothermal and Anti-Inflammatory Therapy.International journal of nanomedicine · 2024Article
- Biomolecule-functionalized nanoformulations for prostate cancer theranostics.Journal of advanced research · 2023Review
- Synergistic action of lactoferrin in enhancing the safety and effectiveness of docetaxel treatment against prostate cancer.Cancer chemotherapy and pharmacology · 2023Article
- Multifunctional nanoparticle for cancer therapy.MedComm · 2023Review
- Computable structured aptamer for targeted treatment of ovarian cancer.Frontiers in genetics · 2023Article
- Nanoparticles as Physically- and Biochemically-Tuned Drug Formulations for Cancers Therapy.Cancers · 2022Review
- Progress in cancer drug delivery based on AS1411 oriented nanomaterials.Journal of nanobiotechnology · 2022Review
- DNA aptamer-based dual-responsive nanoplatform for targeted MRI and combination therapy for cancer.RSC advances · 2022Article
- Advances and Potentials of Polydopamine Nanosystem in Photothermal-Based Antibacterial Infection Therapies.Frontiers in pharmacology · 2022Review
- Recent developments in mesoporous polydopamine-derived nanoplatforms for cancer theranostics.Journal of nanobiotechnology · 2021Review
- Aptamer-conjugated mesoporous polydopamine for docetaxel targeted delivery and synergistic photothermal therapy of prostate cancer.Cell proliferation · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesIt is imperative to develop efficient strategies on the treatment of prostate cancer. Here, we constructed multifunctional nanoparticles, namely AS1411@MPDA-DTX (AMD) for targeted and synergistic chemotherapy/photothermal therapy of prostate cancer. MATERIALS AND
methodsMesoporous polydopamine (MPDA) nanoparticles were prepared by a one-pot synthesis method, DTX was loaded through incubation, and AS1411 aptamer was modified onto MPDA by the covalent reaction. The prepared nanoparticles were characterized by ultra-micro spectrophotometer, Fourier transform infrared spectra, transmission electron microscope, and so on. The targeting ability was detected by selective uptake and cell killing. The mechanism of AMD-mediated synergistic therapy was detected by Western blot and immunofluorescence.
resultsThe prepared nanoparticles can be easily synthesized and possessed excellent water solubility, stability, and controlled drug release ability, preferentially in acidic context. Based on in vitro and in vivo results, the nanoparticles can efficiently target prostate cancer cells, promote DTX internalization, and enhance the antitumor effects of chemo-photothermal therapy strategies under the NIR laser irradiation.
conclusionsAs a multifunctional nanoplatform, AS1411@MPDA-DTX could efficiently target prostate cancer cells, promote DTX internalization, and synergistically enhance the antiprostate cancer efficiency by combining with NIR irradiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.